Binding characteristics of (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)-2-platin um(II) to DNA, RNA and protein molecules in HeLa cells and its lethal effect: comparison with cis- and trans-diamminedichloroplatinums(II)
- PMID: 7508903
- PMCID: PMC5919346
- DOI: 10.1111/j.1349-7006.1994.tb02893.x
Binding characteristics of (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)-2-platin um(II) to DNA, RNA and protein molecules in HeLa cells and its lethal effect: comparison with cis- and trans-diamminedichloroplatinums(II)
Abstract
HeLa S-3 cells were treated with 195mPt-radiolabeled (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato++ +)-2-platinum(II) (DWA2114R) under various conditions, and the relationship between the lethal effect of the agent and the number of platinum (Pt) atoms binding to DNA, RNA and proteins was examined. The values of mean lethal concentration for the cells treated with DWA2114 at 37 degrees C for 1, 2 and 3 h were 137.3, 75.10 and 51.17 microM, respectively. Cells were treated identically and the numbers of Pt atoms combined with DNA, RNA and protein molecules were determined after fractionation of the cells. In this way, the D0 values (D0, dose that would give an average of one lethal event per member of the population), expressed as the drug concentration, were substituted for the number of Pt atoms combined with each fraction. The target volumes, the efficacy of Pt atom to kill cells expressed as the reciprocals of the D0 values, were then calculated for each fraction. Our findings suggested that DNA was the primary target molecule for cell killing by DWA2114R. The target volumes for DNA were 3.36 x 10(4), 4.00 x 10(4) and 4.10 x 10(4) nucleotides for 1-, 2- and 3-h treated cells, respectively. The cell-killing effects of DWA2114R were lower than those of cis-diamminedichloroplatinum(II) (CDDP) by factors of 1.54, 1.42 and 2.51 for 1-, 2- and 3-h treatments at 37 degrees C, respectively, in terms of the target volume, while those in terms of the mean lethal dose (D0) were 14.8, 11.2 and 16.0, respectively. The efficacy of DWA2114R in killing the cells was 2.6 times greater than that of CDDP in the 3-h treatment at 0 degrees C.
Similar articles
-
Determination of the target volume of HeLa cells treated with platinum-195 m radiolabeled cis-diammine(1, 1-cyclobutane-dicarboxylato)-platinum(II); comparison with cis- and trans-diamminedichloroplatinums(II).Nucl Med Biol. 1994 Oct;21(7):953-8. doi: 10.1016/0969-8051(94)90084-1. Nucl Med Biol. 1994. PMID: 9234349
-
Cell-killing efficiency and number of platinum atoms binding to DNA, RNA and protein molecules of HeLa cells treated with combinations of trans-diaminedichloroplatinum(II) and hyperthermia.Jpn J Cancer Res. 1997 May;88(5):506-11. doi: 10.1111/j.1349-7006.1997.tb00410.x. Jpn J Cancer Res. 1997. PMID: 9247608 Free PMC article.
-
The number of platinum atoms binding to DNA, RNA and protein molecules of HeLa cells treated with cisplatin at its mean lethal concentration.Jpn J Cancer Res. 1992 May;83(5):522-6. doi: 10.1111/j.1349-7006.1992.tb01959.x. Jpn J Cancer Res. 1992. PMID: 1618702 Free PMC article.
-
Determination of the target volume of HeLa cells treated with platinum-195m radiolabeled trans-diaminedichloroplatinum(II): a comparison with cis-diaminedichloroplatinum(II).Nucl Med Biol. 1993 May;20(4):389-93. doi: 10.1016/0969-8051(93)90068-6. Nucl Med Biol. 1993. PMID: 8504280
-
Platinum anticancer drugs. From serendipity to rational design.Ann Pharm Fr. 2011 Nov;69(6):286-95. doi: 10.1016/j.pharma.2011.10.001. Epub 2011 Nov 8. Ann Pharm Fr. 2011. PMID: 22115131 Review.
Cited by
-
The Protein-Binding Behavior of Platinum Anticancer Drugs in Blood Revealed by Mass Spectrometry.Pharmaceuticals (Basel). 2021 Jan 29;14(2):104. doi: 10.3390/ph14020104. Pharmaceuticals (Basel). 2021. PMID: 33572935 Free PMC article. Review.
-
ROS-mediated upregulation of Noxa overcomes chemoresistance in chronic lymphocytic leukemia.Oncogene. 2011 Feb 10;30(6):701-13. doi: 10.1038/onc.2010.441. Epub 2010 Oct 11. Oncogene. 2011. PMID: 20935673 Free PMC article.
-
C-Jun N-terminal kinase signalling pathway in response to cisplatin.J Cell Mol Med. 2016 Nov;20(11):2013-2019. doi: 10.1111/jcmm.12908. Epub 2016 Jul 4. J Cell Mol Med. 2016. PMID: 27374471 Free PMC article. Review.
-
Relationship between cell-killing efficiency and number of platinum atoms binding to DNA, RNA, and protein molecules in HeLa cells treated with cis-diamine(glycolato)platinum(II).Jpn J Cancer Res. 1996 Feb;87(2):178-83. doi: 10.1111/j.1349-7006.1996.tb03156.x. Jpn J Cancer Res. 1996. PMID: 8609067 Free PMC article.
-
c‑Jun N‑terminal kinase inhibition attenuates early brain injury induced neuronal apoptosis via decreasing p53 phosphorylation and mitochondrial apoptotic pathway activation in subarachnoid hemorrhage rats.Mol Med Rep. 2019 Jan;19(1):327-337. doi: 10.3892/mmr.2018.9640. Epub 2018 Nov 9. Mol Med Rep. 2019. PMID: 30431087 Free PMC article.
References
-
- ) Wiltshaw , E. and Kroner , T.Phase II study of cis‐diamminedichloroplatinum(II) (NSC‐119875) in advanced adenocarcinoma of ovary . Cancer Treat, Rep. , 60 , 55 – 60 ( 1976. ). - PubMed
-
- ) Einhorn , L. H. and Donohue , J.cis‐Diamminedichloroplatinum, vinblastine and bleomycin in combination chemotherapy in disseminated testicular cancer . Ann. Intern. Med. , 87 , 293 – 298 ( 1977. ). - PubMed
-
- ) Roberts , J. J. and Tompson , A. J.The mechanism of action of antitumor platinum compounds . Prog. Nucleic Acid Res. Mol. Biol. , 22 , 71 – 133 ( 1979. ). - PubMed
-
- ) Lohrer , P. J. and Einhorn , L. H.Cisplatin . Ann. Intern. Med. , 100 , 704 – 713 ( 1984. ). - PubMed
-
- ) Broomhead , J. A. , Fairlie , D. P. and Whitehouse , M. W.cis‐Platinum(II) amine complexes: some structure‐activity relationships for immunosuppressive, nephrotoxic and gastrointestinal (side) effects in rats . Chem.-Biol. Interact. , 31 , 113 – 132 ( 1980. ). - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources